Inhibrx Announces Participation in Upcoming Scientific Conferences
PR Newswire•13/10/2026•16:00 ET
0
Key Highlights
- ➤Oct. 25: Phase 2 primary analysis of ordastobart plus pembrolizumab in 1L R/M HNSCC
- ➤Oct. 29: Ozekibart ChonDRAgon study secondary efficacy endpoints presented in chondrosarcoma
- ➤Nov. 20: Updated PFS and subgroup analysis for ozekibart in chondrosarcoma
- ➤Nov. 19: Phase 1/2 ozekibart combination study in Ewing sarcoma presented
Inhibrx Announces Participation in Upcoming Scientific Conferences PR Newswire
SAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences:
Get started
Create a free account to read the full story.